Sign Up to like & get
recommendations!
0
Published in 2021 at "Revue des maladies respiratoires"
DOI: 10.1016/j.rmr.2021.12.002
Abstract: INTRODUCTION The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to…
read more here.
Keywords:
induced osimertinib;
lung;
pulmonary manifestations;
manifestations induced ... See more keywords